Form 4: Core Laboratories SVP, Gwendolyn Gresham, Reports Acquisition of Performance Shares

Sentiment:

SEC Form 4


Gwendolyn Gresham, SVP of Core Laboratories, reports the acquisition of 32,912 performance shares tied to the company's Return on Invested Capital (ROIC) relative to its Bloomberg Peer Group.

Summary

  • Gwendolyn Gresham, a Senior Vice President at Core Laboratories, filed a Form 4 on February 13, 2025, reporting a transaction involving performance shares.
  • She acquired 32,912 performance shares on February 13, 2025, which will vest based on Core Laboratories' ROIC performance compared to its Bloomberg Peer Group (BPG) over a three-year period from January 1, 2025, to December 31, 2027.
  • The vesting schedule is tiered: 50% of the award vests if the company is in the top 35th percentile of ROIC among the BPG, 100% vests if in the top 55th percentile, and 175% vests if at or above the 85th percentile.
  • The number of shares vesting will be interpolated on a straight-line basis between the 35th and 55th percentiles and again between the 55th and 85th percentiles.
  • The maximum vesting amount (over 100% up to 175%) will be reduced by half if the absolute total shareholder return is negative during the performance period.
  • The shares will vest, if at all, on January 1, 2028, following the conclusion of the performance period.
  • The award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a transaction. However, the use of performance-based compensation is generally viewed positively as it aligns management interests with shareholder value. The potential for significant vesting if the company outperforms its peers is also a positive signal.

Positives

  • The performance-based vesting aligns executive compensation with company performance and shareholder returns.
  • The tiered vesting schedule incentivizes significant outperformance relative to peers.
  • The provision for vesting upon death, disability, termination without cause, or retirement provides some security for the executive.

Risks

  • The ultimate value of the performance shares is dependent on Core Laboratories' ROIC performance, which is subject to market conditions and company execution.
  • Negative total shareholder return during the performance period could significantly reduce the vesting amount.
  • The performance shares will not vest if the company's ROIC does not meet the minimum threshold of the top 35th percentile of its peer group.

Future Outlook

The vesting of the performance shares is contingent on Core Laboratories' future ROIC performance relative to its Bloomberg Peer Group over the period from January 1, 2025, to December 31, 2027.

Industry Context

Performance-based compensation is a common practice in the oilfield services industry to align executive incentives with shareholder value creation. ROIC is a widely used metric to assess the efficiency of capital allocation and profitability.

Comparison to Industry Standards

  • Many companies in the oilfield services sector, such as Schlumberger, Halliburton, and Baker Hughes, utilize performance-based equity awards tied to metrics like ROIC, revenue growth, or total shareholder return.
  • The specific vesting thresholds and performance periods vary across companies, but the general principle of linking executive compensation to key performance indicators is consistent.
  • The use of a peer group comparison is also a common practice to ensure that performance is evaluated relative to industry benchmarks.

Stakeholder Impact

  • Shareholders: The performance-based compensation structure aims to align management's interests with shareholder value creation.
  • Employees: The potential for significant executive compensation based on company performance could incentivize employees to contribute to achieving ROIC targets.

Key Dates

DateDescription
January 1, 2025Start of the three-year performance period for the performance shares.
February 13, 2025Date of the transaction (acquisition of performance shares) and filing of Form 4.
December 31, 2027End of the three-year performance period.
January 1, 2028Date the performance shares will vest, if at all, following the conclusion of the performance period.

Keywords

performance shares, ROIC, Core Laboratories, Gresham, Form 4, vesting, Bloomberg Peer Group, executive compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.